|
The Drug Enforcement Administration (DEA), in coordination with the Department of Health and Human Services, issued an extension of COVID-era telemedicine flexibilities for prescribing controlled medications through December 31, 2026, which were previously set to expire on December 31, 2025. This extension is intended to give the DEA time to finalize telemedicine prescribing regulations to ensure a smooth transition for patients and providers. Absent Congressional action, other COVID-era Medicare telehealth flexibilities will expire on January 30, 2026, including:
- The ability to see a patient in their home, regardless of geographic location
- An expanded list of eligible practitioners
MGMA has long advocated for expanding coverage and reimbursement of virtual services to increase patient access to care. Contact your congressional representatives and urge them to extend these telehealth flexibilities and work toward a permanent solution.
|